Affymetrix Announces Management Changes
April 19 2006 - 3:40PM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) announced today that President and
Director, Susan E. Siegel, is transitioning from her current role
and will continue with the company as President Emeritus, serving
as an advisor and reporting to Stephen P.A. Fodor, Ph.D., founder,
chairman and CEO. Effective immediately, Thane Kreiner, Ph.D., has
been named Senior Vice President of Marketing and Sales, reporting
to the CEO. "Sue has been very instrumental in building the
commercial organization and the company," said Dr. Fodor. "She has
been key to Affymetrix' evolution from a small company to a more
than $350 million global enterprise. We look forward to Sue's
continued involvement in an advisory role." Siegel joined
Affymetrix in 1998 as Senior Vice President of Sales and Marketing
and oversaw the successful build up of Affymetrix' global
commercial infrastructure. In 1999, Siegel was promoted to
President and in 2001, she became a board member. After joining
Affymetrix in 1993, Dr. Kreiner has held numerous roles in the
company, including heading sales and marketing and project
management. "Thane has been a key player in developing many new
market opportunities for Affymetrix. His excellent life-science
domain knowledge and understanding of our technology and customers
make him uniquely qualified to lead this important function," said
Dr. Fodor. In addition, Richard P. Rava, Ph.D., the scientific
co-founder of Affymetrix, has been appointed to head Product
Development. "Rich has been a pioneer in the design and development
of microarray technologies for more than twelve years at
Affymetrix. His experience and technical leadership will provide
the necessary skills to deliver advanced scientific products to the
market place," said Dr. Fodor. About Affymetrix Affymetrix
scientists invented the world's first microarray in 1989 and began
selling the first commercial microarray in 1994. Since then,
Affymetrix GeneChip(R) technology has become the industry standard
in molecular biology research. Affymetrix technology is used by the
world's top pharmaceutical, diagnostic and biotechnology companies,
as well as by leading academic, government and not-for-profit
research institutes. More than 1,400 GeneChip systems have been
shipped around the world and more than 4,000 peer-reviewed papers
have been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the highest
information capacity available today on an array, enabling
researchers to use a whole-genome approach to analyze the
relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The company maintains
important sales and marketing operations in Europe and Asia and has
about 1,000 employees worldwide. For more information about
Affymetrix, please visit the company's Web site at
www.affymetrix.com. NOTE: Affymetrix, the Affymetrix logo and
GeneChip are registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024